Previsão

O preço-alvo médio dos analistas é € 16,81 (+9,73%). A mediana é € 16,81 (+9,73%).

Comprar	4
Manter	10
Vender	0

Notícias Ir para o feed de notícias

Kenvue pays quarterly dividend of $0.21 on Oct. 2

Kenvue's board of directors approved a quarterly dividend of $0.21 per common share. The payment will be made on October 2, 2026, to shareholders of record at the close of business on September 21, 2026. » Mais em de.investing.com
Kenvue raises quarterly dividend by 1.2% to $0.21

Kenvue has increased the quarterly dividend by 1.2% to $0.21 per common share. The payment will be made on August 26, 2026, to shareholders of record on August 12, 2026. Kenvue operates in the consumer health sector and owns brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena and Tylenol. » Mais em de.investing.com
Federal appeals court reinstates Tylenol lawsuits against Kenvue — stock falls

A three-judge panel in New York vacated the dismissal of suits against Kenvue and sent the case back for further proceedings, saying the lower court apparently exceeded its discretion when excluding three expert witnesses. Plaintiffs accuse Kenvue of concealing risks of a link between Tylenol use during pregnancy and autism; in 2023 about 500 suits had already been partly dismissed. Resuming the cases could lead to thousands more filings; a potential settlement could cost billions, Bloomberg Intelligence says. Kenvue shares fell about 1% on Monday. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, Kenvue já distribuiu € 0,54 em dividendos. A última distribuição ocorreu em agosto.

Dados financeiros da empresa

No último trimestre, Kenvue registou receitas de € 3,47 bi e um ganho líquido de € 400,49 mi

(EUR)	junho de 2026	YoY
Receitas	3,47 bi	6,10%
Ganho bruto	2,02 bi	4,81%
Ganho líquido	400,49 mi	11,82%
EBITDA	731,59 mi	2,50%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 29,44 bi
Número de ações	1,92 bi
Máximo/mínimo de 52 semanas	€ 17,35 - € 12,08
Rentabilidade de dividendos	4,65%
Dividendos TTM	€ 0,71
Próximo dividendo	€ 0,18
Beta	0,43
PER (PE Ratio)	20,45
PEG (PEG Ratio)	1,16
P/VC (PB Ratio)	3,24
P/V (PS Ratio)	2,22

Perfil da empresa

Kenvue Inc. ist ein weltweit tätiges Unternehmen im Bereich der Verbrauchergesundheit. Das Unternehmen ist in drei Segmenten tätig: Self Care, Skin Health and Beauty und Essential Health. Das Segment Self Care bietet unter den Marken Tylenol, Nicorette und Zyrtec Produkte zur Behandlung von Husten, Erkältungen und Allergien, zur Schmerzbehandlung, für die Verdauung, zur Raucherentwöhnung und andere Produkte an. Das Segment Skin Health and Beauty bietet unter den Markennamen Neutrogena, Aveeno und OGX Gesichts- und Körperpflege, Haarpflege sowie Sonnen- und andere Pflegeprodukte an. Das Segment Essential Health bietet unter den Marken Listerine, Johnson's, Band-Aid und Stayfree Produkte für die Mund- und Babypflege, die Gesundheit von Frauen und die Wundpflege an. Das Unternehmen wurde im Jahr 2022 gegründet und hat seinen Hauptsitz in Skillman, New Jersey. Kenvue Inc. arbeitet als Tochtergesellschaft von Johnson & Johnson.

Nome	Kenvue
CEO	Kirk L. Perry
Sede	Summit, nj EUA
Site	kenvue.com
Setor	Bens de consumo básico
Indústria	Bens de consumo básico: distribuição e retalho
Entrada em bolsa	04/05/2023
Colaboradores	21.890